Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.4% in the afternoon session after investors took some ...

We recently published 10 Stocks That Vanished in Value Hims & Hers Health, Inc. (NYSE:HIMS) is one of the worst-performing ...

In Q2 2025, Hims & Hers reported adjusted earnings of $0.17 per share, topping estimates of $0.15. Revenue rose 73% year-over ...

Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 3.6% in the afternoon session after the disclosure of significant stock sales by top executives, including CEO Andrew Dudum. According ...

Hims & Hers Health’s second quarter results were met with a significant negative market reaction, as sales growth lagged Wall Street’s expectations despite a strong rise in non-GAAP profitability.

Hims & Hers Health ( NYSE: HIMS) shares traded lower for the second straight session on Tuesday after the telehealth firm’s ...

NVIDIA Corporation, Novo Nordisk A/S, Shift4 Payments Inc, Hims Hers Health Inc. Read 's Market Analysis on Investing.com ...

What Happened: According to a Form 4 filing with the U.S. Securities and Exchange Commission on Monday, Dudum sold 660,000 shares of Hims & Hers Health. The total transaction value is $33,384,120. The ...

It's a strong statement to make, and Hims & Hers management, led by CEO Andrew Dudum, isn't wasting any time in responding. The argument centers around Novo Nordisk's weight loss drug, Wegovy.

Andrew Dudum, Hims chief executive, said there was a “huge opportunity” in obesity as he announced the acquisition of European rival Zava, which already sells some weight-loss treatments.